 Clinical Phase III study to investigate the feasibility and tolerability of synthetic adjuvant peptide immunisation in combination with immune adjuvants granulocyte macrophage colony stimulating factor; Montanide ISA-51 in patients with advanced renal cell cancer RCC. 